GILD · News · 20260825N
Oncology Product Expansion
GILEAD SCIENCES, INC. · 2026-08-25 · Importance 16 · Surprise 60 · In source text
The European Commission approved a label expansion for Gilead’s Trodelvy in combination with Merck’s Keytruda. The approval covers first-line treatment of metastatic triple-negative breast cancer (TNBC) in the European Union. The expanded indication strengthens Trodelvy’s potential oncology growth opportunity by broadening its use into earlier-line metastatic TNBC treatment.
Key facts
- Trodelvy's latest EU approval with Keytruda expands its first-line metastatic TNBC use. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | committed | — | Trodelvy's latest EU approval with Keytruda expands its first-line metastatic TNBC use. |